 Several studies have shown beneficial effect of ASA on primary prevention of CRC and the investigators group and others have shown a potential association of ASA also taken after the diagnosis on CRC survival in registry-based studies secondary prevention. Up to 800 patients operated for CRCLM will be randomized to Arm1 ASA 160 mg once daily or Arm2 Placebo for a period of 3 years or till disease recurrence. The patients will be treated and followed up according to standard of care and the National Guidelines. 